• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特应性皮炎疾病严重程度的结局指标。

Outcome measures of disease severity in atopic eczema.

作者信息

Charman C, Williams H

机构信息

Department of Dermatology, Queen's Medical Centre, Nottingham, England.

出版信息

Arch Dermatol. 2000 Jun;136(6):763-9. doi: 10.1001/archderm.136.6.763.

DOI:10.1001/archderm.136.6.763
PMID:10871941
Abstract

BACKGROUND

An essential component of evidence-based medicine is the use of valid and reliable outcome measures in clinical trials. There is much confusion in the field of atopic eczema regarding how to best measure disease severity objectively.

OBJECTIVE

To establish the extent to which existing objective clinical scales for atopic eczema have been tested for validity, reliability, sensitivity to change, and acceptability.

DESIGN

An electronic bibliographic search was performed for published data on all currently available named atopic eczema scales.

RESULTS

Thirteen scales were identified in total. Data on construct or criterion validity were available for 10 scales. Only 5 scales had been tested for reliability (interobserver variability, intraobserver variability, or internal consistency). Data on responsiveness to change were available for 8 scales. An estimated time to administer the measure had been given for 3 scales. The only severity scale for which published data could be found on validity, reliability, sensitivity, and acceptability testing was the Severity Scoring of Atopic Dermatitis index, although problems occurred with interobserver variation of the index.

CONCLUSION

The rapidly increasing number of severity scales for atopic eczema, many of which have been inadequately tested, has made the interpretation of patient outcomes confusing, and comparison of results between studies almost impossible. Consensus among clinicians and researchers on the use of severity scales for atopic eczema should be based on evidence of adequate validity), reliability, sensitivity to change, and ease of use.

摘要

背景

循证医学的一个重要组成部分是在临床试验中使用有效且可靠的结局指标。在特应性皮炎领域,对于如何最好地客观测量疾病严重程度存在很多困惑。

目的

确定现有的特应性皮炎客观临床量表在有效性、可靠性、对变化的敏感性和可接受性方面的测试程度。

设计

对所有当前可用的特应性皮炎命名量表的已发表数据进行电子文献检索。

结果

总共确定了13个量表。10个量表有关于结构效度或标准效度的数据。只有5个量表进行了可靠性测试(观察者间变异性、观察者内变异性或内部一致性)。8个量表有关于对变化的反应性的数据。3个量表给出了估计的测量实施时间。唯一能找到关于效度、可靠性、敏感性和可接受性测试的已发表数据的严重程度量表是特应性皮炎严重程度评分指数,尽管该指数存在观察者间差异的问题。

结论

特应性皮炎严重程度量表的数量迅速增加,其中许多量表测试不充分,这使得对患者结局的解释变得混乱,并且几乎不可能在研究之间比较结果。临床医生和研究人员就特应性皮炎严重程度量表的使用达成共识应基于充分的效度、可靠性、对变化的敏感性和易用性的证据。

相似文献

1
Outcome measures of disease severity in atopic eczema.特应性皮炎疾病严重程度的结局指标。
Arch Dermatol. 2000 Jun;136(6):763-9. doi: 10.1001/archderm.136.6.763.
2
Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.特应性皮炎临床体征评估:系统评价和建议。
J Allergy Clin Immunol. 2013 Dec;132(6):1337-47. doi: 10.1016/j.jaci.2013.07.008. Epub 2013 Sep 12.
3
What are the best outcome measurements for atopic eczema? A systematic review.特应性皮炎的最佳疗效指标有哪些?一项系统评价。
J Allergy Clin Immunol. 2007 Dec;120(6):1389-98. doi: 10.1016/j.jaci.2007.08.011. Epub 2007 Oct 1.
4
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.特应性皮炎临床试验中评估临床体征的湿疹结局指标(HOME)声明。
J Allergy Clin Immunol. 2014 Oct;134(4):800-7. doi: 10.1016/j.jaci.2014.07.043.
5
Reliability testing of the Six Area, Six Sign Atopic Dermatitis severity score.六区域、六体征特应性皮炎严重程度评分的可靠性测试。
Br J Dermatol. 2002 Jun;146(6):1057-60. doi: 10.1046/j.1365-2133.2002.04644.x.
6
Giving "scale" new meaning in dermatology: measurement matters.
Arch Dermatol. 2000 Jun;136(6):788-90. doi: 10.1001/archderm.136.6.788.
7
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.特应性皮炎验证研究者全球评估(vIGA-AD):一种新的特应性皮炎严重程度临床结局测量工具的开发和可靠性测试。
J Am Acad Dermatol. 2020 Sep;83(3):839-846. doi: 10.1016/j.jaad.2020.04.104. Epub 2020 Apr 25.
8
The objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis.成人特应性皮炎客观严重程度评估(OSAAD)评分:在成人特应性皮炎患者中的有效性、可靠性和敏感性
Br J Dermatol. 2005 Oct;153(4):767-73. doi: 10.1111/j.1365-2133.2005.06697.x.
9
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group.湿疹面积及严重程度指数(EASI):特应性皮炎中的可靠性评估。EASI评估者小组。
Exp Dermatol. 2001 Feb;10(1):11-8. doi: 10.1034/j.1600-0625.2001.100102.x.
10
Assessing the severity of atopic dermatitis in clinical trials and practice.在临床试验和实践中评估特应性皮炎的严重程度。
Clin Dermatol. 2018 Sep-Oct;36(5):606-615. doi: 10.1016/j.clindermatol.2018.05.012. Epub 2018 Jun 1.

引用本文的文献

1
Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.2%克立硼罗软膏治疗中国≥2岁轻度至中度特应性皮炎患者的疗效和安全性
Dermatol Ther (Heidelb). 2024 May;14(5):1229-1243. doi: 10.1007/s13555-024-01156-6. Epub 2024 May 15.
2
Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research: an interdisciplinary perspective.特应性皮炎和银屑病的疾病严重程度定义:应用于生物标志物研究的跨学科视角。
Br J Dermatol. 2024 Jun 20;191(1):14-23. doi: 10.1093/bjd/ljae080.
3
Advancements in Allergen Immunotherapy for the Treatment of Atopic Dermatitis.
用于治疗特应性皮炎的变应原免疫疗法的进展
Int J Mol Sci. 2024 Jan 21;25(2):1316. doi: 10.3390/ijms25021316.
4
Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials.评估特应性皮炎的反应:对卫生技术评估和临床试验中使用的测量方法的心理测量性能的系统评价。
Dermatol Ther (Heidelb). 2023 Nov;13(11):2549-2571. doi: 10.1007/s13555-023-01038-3. Epub 2023 Sep 25.
5
Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis.皮肤型红斑狼疮和皮肌炎的流行病学及临床评估工具的最新进展
Curr Dermatol Rep. 2013 Mar;2(1):48-57. doi: 10.1007/s13671-012-0037-3. Epub 2013 Jan 24.
6
Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?度普利尤单抗治疗特应性皮炎:我们一直在寻找的万灵药?
Cureus. 2020 Apr 6;12(4):e7565. doi: 10.7759/cureus.7565.
7
Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.使用特应性皮炎严重程度指数和体表面积受累百分比评估克立硼罗的疗效。
Acta Derm Venereol. 2020 Jun 11;100(13):adv00170. doi: 10.2340/00015555-3489.
8
Efficacy of health education on treatment of children with atopic dermatitis: a meta-analysis of randomized controlled trials.健康教育对治疗儿童特应性皮炎疗效的 Meta 分析:随机对照试验研究
Arch Dermatol Res. 2020 Dec;312(10):685-695. doi: 10.1007/s00403-020-02060-7. Epub 2020 Apr 15.
9
Dioscorea quinqueloba Ameliorates Oxazolone- and 2,4-Dinitrochlorobenzene-induced Atopic Dermatitis Symptoms in Murine Models.穿龙薯蓣改善小鼠模型中恶唑酮和 2,4-二硝基氯苯诱导的特应性皮炎症状。
Nutrients. 2017 Dec 5;9(12):1324. doi: 10.3390/nu9121324.
10
Clinical Signs, Staphylococcus and Atopic Eczema-Related Seromarkers.临床体征、葡萄球菌与特应性皮炎相关血清标志物
Molecules. 2017 Feb 14;22(2):291. doi: 10.3390/molecules22020291.